Sumatriptan vs. Ubrelvy
See how Sumatriptan and Ubrelvy compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Sumatriptan and Ubrelvy both treat a migraine attack after it starts rather than preventing future attacks, but they work through very different mechanisms.
Sumatriptan narrows blood vessels and is unsafe for people with heart disease or stroke history, while Ubrelvy avoids this vascular risk entirely.
Sumatriptan typically costs far less out of pocket than Ubrelvy, which can run over a thousand dollars a month without insurance.
Sumatriptan vs. Ubrelvy Drug Summary
Sumatriptan
Sumatriptan is a triptan that narrows blood vessels in the brain and blocks pain signals to stop a migraine attack once it starts. It is taken as a single oral tablet in one of three strengths per attack, and is also available as an injection or nasal spray. Approved in 1992, it is one of the most affordable migraine medications on the market.
Ubrelvy
Ubrelvy (ubrogepant) is a CGRP receptor antagonist, or gepant, that blocks a protein involved in migraine pain instead of narrowing blood vessels. It is taken as an oral tablet at the first sign of a migraine, with a second dose allowed at least two hours later if needed. Approved in 2019, it offers an acute treatment option for people who cannot take triptans.
Sumatriptan vs. Ubrelvy Side Effects
Sumatriptan
Ubrelvy
Sumatriptan vs. Ubrelvy Dosage
Sumatriptan
Ubrelvy
| STAGE | DOSE | WHEN |
| Starting dose | 25 mg once per attack | At the start |
| Maximum dose | 25 mg once per attack | Same as starting |
| Dose changes | None | Fixed dose |
| STAGE | DOSE | WHEN |
| Starting dose | 50 mg or 100 mg orally | At the start |
| Maximum dose | 50 mg or 100 mg (2nd dose) | If needed |
| Dose changes | 1 increase | As tolerated |
Sumatriptan
| STAGE | DOSE | WHEN |
| Starting dose | 25 mg once per attack | At the start |
| Maximum dose | 25 mg once per attack | Same as starting |
| Dose changes | None | Fixed dose |
Ubrelvy
| STAGE | DOSE | WHEN |
| Starting dose | 50 mg or 100 mg orally | At the start |
| Maximum dose | 50 mg or 100 mg (2nd dose) | If needed |
| Dose changes | 1 increase | As tolerated |
Sumatriptan vs. Ubrelvy Indications
Sumatriptan
Sumatriptan is FDA-approved for the acute treatment of migraine with or without aura in adults. It is not approved to prevent future migraines or to treat cluster headaches in tablet form.
Treats a migraine attack already in progress
Not approved for migraine prevention
Not approved for cluster headache (tablet form)
Available as tablet, injection, or nasal spray
Ubrelvy
Ubrelvy is FDA-approved for the acute treatment of migraine with or without aura in adults. It is not approved to prevent migraines and has not been studied in children.
Treats a migraine attack already in progress
Not approved for migraine prevention
Not approved for pediatric patients
Oral tablet only
Sumatriptan vs. Ubrelvy Pros and Cons
Sumatriptan
Sumatriptan has decades of clinical use and comes in tablet, injection, and nasal spray forms, giving flexibility for different attack severities. It is one of the most affordable migraine treatments available, but its blood vessel-narrowing effect rules it out for people with cardiovascular risk factors.
Pros
Available as tablet, injection, or nasal spray for flexible dosing
Decades of real-world use since 1992
Roughly $12 to $185 per 9 tablets, much cheaper than Ubrelvy
Cons
Contraindicated with history of heart disease, stroke, or Prinzmetal's angina
Cannot be combined with ergotamines or other 5-HT1 agonists within 24 hours
Risk of serotonin syndrome with other serotonergic medications
Vasoconstriction risk makes it unsuitable for some patients
Ubrelvy
Ubrelvy targets the CGRP pathway instead of narrowing blood vessels, making it an option for people who cannot take triptans because of cardiovascular risk. It is only available as a tablet and costs significantly more than sumatriptan without insurance coverage.
Pros
No cardiovascular contraindications, unlike triptans
Second dose allowed if the first doesn't fully resolve symptoms
No vasoconstriction risk since it targets CGRP, not blood vessels
Cons
Roughly $1,085 to $1,140 per month without insurance, far more than sumatriptan
Requires dose adjustments with CYP3A4 inhibitors, inducers, or grapefruit juice
Only available as an oral tablet, with no injection or nasal option
New-onset hypertension or Raynaud's phenomenon may occur
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.